HomeCompareRCOR vs GBDC

RCOR vs GBDC: Dividend Comparison 2026

RCOR yields 62.50% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.04M in total portfolio value· pulled ahead in Year 7
10 years
RCOR
RCOR
● Live price
62.50%
Share price
$3.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$735.9K
Annual income
$177,443.13
Full RCOR calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — RCOR vs GBDC

📍 GBDC pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRCORGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RCOR + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RCOR pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RCOR
Annual income on $10K today (after 15% tax)
$5,312.50/yr
After 10yr DRIP, annual income (after tax)
$150,826.66/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $13,780,047.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RCOR + GBDC for your $10,000?

RCOR: 50%GBDC: 50%
100% GBDC50/50100% RCOR
Portfolio after 10yr
$10.76M
Annual income
$8,283,353.26/yr
Blended yield
77.01%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

RCOR
Analyst Ratings
2
Buy
Consensus: Buy
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RCOR buys
0
GBDC buys
2
PoliticianChamberTickerTypeAmountDate
David P. Joyce🏢 House$GBDC▼ Sell$1,001 - $15,0002023-06-30
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002023-06-19
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002022-07-14
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002022-07-12
Teresa Leger Fernandez🏢 House$GBDC▼ Sell$15,001 - $50,0002021-01-20
David P. Joyce🏢 House$GBDC▲ Buy$1,001 - $15,0002020-02-25
David P. Joyce🏢 House$GBDC▲ Buy$15,001 - $50,0002019-05-30
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRCORGBDC
Forward yield62.50%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$735.9K$20.78M
Annual income after 10y$177,443.13$16,389,263.41
Total dividends collected$614.9K$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: RCOR vs GBDC ($10,000, DRIP)

YearRCOR PortfolioRCOR Income/yrGBDC PortfolioGBDC Income/yrGap
1$16,950$6,250.00$12,490$1,790.28+$4.5KRCOR
2$28,037$9,900.70$16,522$3,157.73+$11.5KRCOR
3$45,305$15,305.49$23,578$5,898.68+$21.7KRCOR
4$71,591$23,114.13$37,115$11,886.75+$34.5KRCOR
5$110,737$34,135.17$66,136$26,423.57+$44.6KRCOR
6$167,835$49,346.36$137,257$66,491.44+$30.6KRCOR
7← crossover$249,481$69,897.34$341,734$194,868.54$92.3KGBDC
8$364,047$97,102.68$1,050,788$685,133.02$686.7KGBDC
9$521,955$132,424.34$4,099,314$2,974,971.01$3.58MGBDC
10$735,935$177,443.13$20,775,530$16,389,263.41$20.04MGBDC

RCOR vs GBDC: Complete Analysis 2026

RCORStock

Renovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut.

Full RCOR Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this RCOR vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RCOR vs SCHDRCOR vs JEPIRCOR vs ORCOR vs KORCOR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.